Elapegademase-lvlr (Revcovi)

Revcovi (elapegademase-lvlr) is covered only for the FDA‑approved indication of ADA‑SCID in pediatric and adult patients and is not covered for non‑FDA‑approved (off‑label) uses. Coverage requires documented ADA‑SCID by either molecular genetic testing showing bi‑allelic ADA mutations or baseline ADA catalytic activity <1%, prescription by or in consultation with an immunologist/hematologist‑oncologist or ADA‑SCID specialist, intramuscular administration with a maximum cumulative dose of 0.4 mg/kg per week (may be divided into multiple injections), appropriate weight and prescription documentation, and approvals are issued for up to 12 months.

"Revcovi is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients."

Sign up to see full coverage criteria, indications, and limitations.